Hemo Organic has informed that it submitted unaudited standalone financial results along with limited review report for the quarter ended on December 31, 2023 on February 12, 2024. However, due to typo graphical error in limited review report, the reporting period was mentioned as December, 2024 instead of December, 2023. Therefore, it attached revised Unaudited standalone limited review report for the quarter ended on December 31, 2023, to rectify the typo graphical error occurred in the period mentioned in limited review report December, 2024 instead of December, 2023. Further, there is no change in data provided earlier except period mentioned in the limited review report. In this regard, it submitted Revised Limited Review Report for the quarter ended on December 31, 2023.
The above information is a part of company’s filings submitted to BSE.